Registro:

Referencias:

• Drexler, I., Heller, K., Wahren, B., Erfle, V., Sutter, G., Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells (1998) J. Gener. Virol, 79, pp. 347-352
• Carroll, M.W., Moss, B., Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line (1997) Virolog, 238, pp. 198-211
• McCurdy, L.H., Larkin, B.D., Martin, J.E., Graham, B.S., Modified vaccinia Ankara: Potential as an alternative smallpox vaccine (2004) Clin. Infect. Di, 38, pp. 1749-1753
• Antoine, G., Scheiflinger, F., Dorner, F., Falkner, F.G., The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses (1998) Virolog, 244, pp. 365-396
• Blanchard, T.J., Alcami, A., Andrea, P., Smith, G.L., Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine (1998) J. Gener. Virol, 79, pp. 1159-1167
• Dobson, B.M., Tscharke, D.C., Truncation of gene F5L partially masks rescue of vaccinia virus strain MVA growth on mammalian cells by restricting plaque size (2014) J. Gener. Viro, 95, pp. 466-471
• Gomez, C.E., Perdiguero, B., Garcia-Arriaza, J., Esteban, M., Clinical applications of attenuated MVA poxvirus strain. Exp (2013) Rev. Vaccine, 12, pp. 1395-1416
• Acres, B., Bonnefoy, J.Y., Clinical development of MVA-based therapeutic cancer vaccines. Exp (2008) Rev. Vaccine, 7, pp. 889-893
• Sutter, G., Staib, C., Vaccinia vectors as candidate vaccines: The development of modified vaccinia virus Ankara for antigen delivery (2003) Curr. Drug Targets Infect. Disor, 3, pp. 263-271
• Gilbert, S.C., Clinical development of modified vaccinia virus Ankara vaccines (2013) Vaccin, 31, pp. 4241-4246
• Hill, A.V., Reyes-Sandoval, A., O’Hara, G., Ewer, K., Lawrie, A., Goodman, A., Nicosia, A., Colloca, S., Prime-boost vectored malaria vaccines: Progress and prospects (2010) Hum. Vaccine, 6, pp. 78-83
• Bejon, P., Ogada, E., Mwangi, T., Milligan, P., Lang, T., Fegan, G., Gilbert, S.C., Hill, A.V., Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya (2007) Plos ON, 2
• Hawkridge, T., Scriba, T.J., Gelderbloem, S., Smit, E., Tameris, M., Moyo, S., Lang, T., Merwe, L., Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa (2008) J. Infect. Dis, 198, pp. 544-552
• Nicol, M.P., Grobler, L.A., MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults (2010) Curr. Opin. Mol. The, 12, pp. 124-134
• Kim, D.W., Krishnamurthy, V., Bines, S.D., Kaufman, H.L., TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4 (2010) Lessons Learned and Future Development. Hum. Vaccine, 6, pp. 784-791
• Dangoor, A., Lorigan, P., Keilholz, U., Schadendorf, D., Harris, A., Ottensmeier, C., Smyth, J., Cripps, M., Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol (2010) Immunothe, 59, pp. 863-873
• Meisinger-Henschel, C., Schmidt, M., Lukassen, S., Linke, B., Krause, L., Konietzny, S., Goesmann, A., Suter, M., Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara (2007) J. Gener. Virol, 88, pp. 3249-3259
• Staib, C., Kisling, S., Erfle, V., Sutter, G., Inactivation of the viral interleukin 1β receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara (2005) J. Gener. Viro, 86, pp. 1997-2006
• Clark, R.H., Kenyon, J.C., Bartlett, N.W., Tscharke, D.C., Smith, G.L., Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy (2006) J. Gener. Virol, 87, pp. 29-38
• Falivene, J., Del Medico Zajac, M.P., Pascutti, M.F., Rodriguez, A.M., Maeto, C., Perdiguero, B., Gomez, C.E., Gherardi, M.M., Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein (2012) Plos ON, 7
• Perdiguero, B., Gomez, C.E., Najera, J.L., Sorzano, C.O., Delaloye, J., Gonzalez-Sanz, R., Jimenez, V., Pantaleo, G., Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens (2012) Plos ON, 7
• Garber, D.A., O’Mara, L.A., Gangadhara, S., McQuoid, M., Zhang, X., Zheng, R., Gill, K., Johnson, B., Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in Rhesus Macaques (2012) J. Viro, 86, pp. 12605-12615
• Garcia-Arriaza, J., Arnaez, P., Gomez, C.E., Sorzano, C.O., Esteban, M., Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways (2013) Plos ON, 8
• Garcia-Arriaza, J., Gomez, C.E., Sorzano, C.O., Esteban, M., Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens (2014) J. Viro, 88, pp. 3392-3410
• Bowie, A., Kiss-Toth, E., Symons, J.A., Smith, G.L., Dower, S.K., O’Neill, L.A., A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling (2000) Proc. Natl. Acad. Sci. US, 97, pp. 10162-10167
• Stack, J., Haga, I.R., Schroder, M., Bartlett, N.W., Maloney, G., Reading, P.C., Fitzgerald, K.A., Bowie, A.G., Vaccinia virus protein A46R targets multiple toll-like-interleukin-1 receptor adaptors and contributes to virulence (2005) J. Exp. Me, 201, pp. 1007-1018
• Ghosh, S., May, M.J., Kopp, E.B., Nf-b and Rel proteins: Evolutionarily conserved mediators of immune responses (1998) Annu. Rev. Immuno, 16, pp. 225-260
• Honda, K., Takaoka, A., Taniguchi, T., Type, I., Interferon gene induction by the interferon regulatory factor family of transcription factors (2006) Immunit, 25, pp. 349-360
• Takeuchi, O., Akira, S., Innate immunity to virus infection (2009) Immunol. Re, 227, pp. 75-86
• Reading, P.C., Moore, J.B., Smith, G.L., Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection (2003) J. Exp. Me, 197, pp. 1269-1278
• Boumpas, D.T., Chrousos, G.P., Wilder, R.L., Cupps, T.R., Balow, J.E., Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates (1993) Ann. Intern. Me, 119, pp. 1198-1208
• Perdiguero, B., Gomez, C.E., Di Pilato, M., Sorzano, C.O., Delaloye, J., Roger, T., Calandra, T., Esteban, M., Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C (2013) Plos ON, 8
• Alharbi, N.K., Spencer, A.J., Hill, A.V., Gilbert, S.C., Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity (2015) Plos ON, 10
• Cottingham, M.G., Andersen, R.F., Spencer, A.J., Saurya, S., Furze, J., Hill, A.V., Gilbert, S.C., Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA) (2008) Plos ON, 3
• Moore, J.B., Smith, G.L., Steroid hormone synthesis by a vaccinia enzyme (1992) A New Type of Virus Virulence Factor. EMBO J, 11, p. 3490
• Sroller, V., Kutinova, L., Nemeckova, S., Simonova, V., Vonka, V., Effect of 3-β-hydroxysteroid dehydrogenase gene deletion on virulence and immunogenicity of different vaccinia viruses and their recombinants (1998) Arch. Viro, 143, pp. 1311-1320
• Tscharke, D.C., Reading, P.C., Smith, G.L., Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes (2002) J. Gener. Viro, 83, pp. 1977-1986
• Almazan, F., Tscharke, D.C., Smith, G.L., The vaccinia virus superoxide dismutase-like protein (A45R) is a virion component that is nonessential for virus replication (2001) J. Viro, 75, pp. 7018-7029
• Mayr, A., Stickl, H., Muller, H.K., Danner, K., Singer, H., The smallpox vaccination strainMVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author’s transl). Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene (1978) Erste Abteilung Original, 167, pp. 375-390
• Earl, P.L., Cooper, N., Wyatt, L.S., Moss, B., Carroll, M.W., Preparation of cell cultures and vaccinia virus stocks (2001) Curr. Protoc. Mol. Bio
• Ramirez, J.C., Gherardi, M.M., Esteban, M., Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of B-and T-cell immune responses in comparison with the western reserve strain and advantages as a vaccine (2000) J. Viro, 74, pp. 923-933
• Tscharke, D.C., Karupiah, G., Zhou, J., Palmore, T., Irvine, K.R., Haeryfar, S.M., Williams, S., Bennink, J.R., Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines (2005) J. Exp. Med, 201, pp. 95-104
• Rodriguez, A.M., Turk, G., Pascutti, M.F., Ferrer, F., Najera, J.L., Monaco, D., Esteban, M., Gherardi, M.M., Characterization of DNA and MVA vectors expressing Nef from HIV-1 CRF12_BF revealed high immune specificity with low cross-reactivity against subtype B (2009) Virus Re, 146, pp. 1-12
• Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, M., Koup, R.A., Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation (2003) J. Immunol. Method, 281, pp. 65-78
• Maeto, C., Rodriguez, A.M., Holgado, M.P., Falivene, J., Gherardi, M.M., Novel mucosal DNA-MVA HIV vaccination in which DNA-IL-12 plus cholera toxin B subunit (CTB) cooperates to enhance cellular systemic and mucosal genital tract immunity (2014) Plos ON, 9
• Rodriguez, A.M., Pascutti, M.F., Maeto, C., Falivene, J., Holgado, M.P., Turk, G., Gherardi, M.M., IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12_BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality (2012) Plos ON, 7
• Nakagawa, Y., Watari, E., Shimizu, M., Takahashi, H., One-step simple assay to determine antigen-specific cytotoxic activities by single-color flow cytometry (2011) Biomed. Re, 32, pp. 159-166
• (2009) Graph Pad Pris, , Version 5.03; GraphPad Software Inc.: LA Jolla, CA, US
• Engelstad, M., Howard, S.T., Smith, G.L., A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope (1992) Virolog, 188, pp. 801-810
• Roper, R.L., Wolffe, E.J., Weisberg, A., Moss, B., The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus (1998) J. Viro, 72, pp. 4192-4204
• Abadie, V., Bonduelle, O., Duffy, D., Parizot, C., Verrier, B., Combadiere, B., Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice (2009) Plos ON, 4
• Zhang, Y., Joe, G., Hexner, E., Zhu, J., Emerson, S.G., Host-reactive CD8+ memory stem cells in graft-versus-host disease (2005) Nat. Me, 11, pp. 1299-1305
• Gattinoni, L., Zhong, X.S., Palmer, D.C., Ji, Y., Hinrichs, C.S., Yu, Z., Wrzesinski, C., Garvin, L.M., Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells (2009) Nat. Me, 15, pp. 808-813
• Seth, R.B., Sun, L., Chen, Z.J., Antiviral innate immunity pathways (2006) Cell Re, 16, pp. 141-147
• Dai, P., Wang, W., Cao, H., Avogadri, F., Dai, L., Drexler, I., Joyce, J.A., Merghoub, T., Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathway (2014) Plos Patho, 10
• Kreijtz, J.H., Gilbert, S.C., Sutter, G., Poxvirus vectors (2013) Vaccin, 31, pp. 4217-4219
• Delaloye, J., Roger, T., Steiner-Tardivel, Q.G., Le Roy, D., Knaup Reymond, M., Akira, S., Petrilli, V., Tschopp, J., Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome (2009) Plos Patho, 5
• Appay, V., Douek, D.C., Price, D.A., CD8+ T cell efficacy in vaccination and disease (2008) Nat. Me, 14, pp. 623-628
• Hickman, H.D., Takeda, K., Skon, C.N., Murray, F.R., Hensley, S.E., Loomis, J., Barber, G.N., Yewdell, J.W., Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes (2008) Nat. Immuno, 9, pp. 155-165
• Perdiguero, B., Gomez, C.E., Cepeda, V., Sanchez-Sampedro, L., Garcia-Arriaza, J., Mejias-Perez, E., Jimenez, V., Sorzano, C.O., Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140 (ZM96) and Gag (ZM96)-Pol-Nef (CN54) as virus-like particles (2015) J. Viro, 89, pp. 970-988
• Delaloye, J., Filali-Mouhim, A., Cameron, M.J., Haddad, E.K., Harari, A., Goulet, J.P., Gomez, C.E., Pantaleo, G., Interleukin-1-and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins (2015) J. Viro, 89, pp. 3819-3832
• Wolferstatter, M., Schweneker, M., Spath, M., Lukassen, S., Klingenberg, M., Brinkmann, K., Wielert, U., Chaplin, P., Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses (2014) J. Viro, 88, pp. 14396-14411
• Watford, W.T., Moriguchi, M., Morinobu, A., O’Shea, J.J., The biology of IL-12: Coordinating innate and adaptive immune responses (2003) Cytokine Growth Factor Re, 14, pp. 361-368
• Pearce, E.L., Shen, H., Generation of CD8 T cell memory is regulated by IL-12 (2007) J. Immuno, 179, pp. 2074-2081
• Agnello, D., Lankford, C.S., Bream, J., Morinobu, A., Gadina, M., O’Shea, J.J., Frucht, D.M., Cytokines and transcription factors that regulate T helper cell differentiation: New players and new insights (2003) J. Clin. Immuno, 23, pp. 147-161
• Ben-Sasson, S.Z., Hu-Li, J., Quiel, J., Cauchetaux, S., Ratner, M., Shapira, I., Dinarello, C.A., Paul, W.E., IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation (2009) Proc. Natl. Acad. Sci. US, 106, pp. 7119-7124
• Ben-Sasson, S.Z., Hogg, A., Hu-Li, J., Wingfield, P., Chen, X., Crank, M., Caucheteux, S., Nir-Paz, R., IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells (2013) J. Exp. Med, 210, pp. 491-502
• Huber, J.P., Farrar, J.D., Regulation of effector and memory T-cell functions by type I interferon (2011) Immunolog, 132, pp. 466-474
• Zhu, J., Martinez, J., Huang, X., Yang, Y., Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-β (2007) Bloo, 109, pp. 619-625
• Frenz, T., Waibler, Z., Hofmann, J., Hamdorf, M., Lantermann, M., Reizis, B., Tovey, M.G., Kalinke, U., Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion (2010) Eur. J. Immunol, 40, pp. 2769-2777

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------